IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy responseSonja Bendig, Lorenz Bastian, Rathana Kim et al.|Blood|2026Cited by 0
Abstract 6057: The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiationRuth W. Wang'ondu, Charles G. Mullighan, Devanand Bondage et al.|Cancer Research|2026Cited by 0